Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.

AusPAR: Pembrolizumab

Australian Public Assessment Report

AusPAR

AusPAR: Pembrolizumab [Keytruda] [PDF, 937.38 KB]

AusPAR: Pembrolizumab [Keytruda] [DOCX, 3.07 MB]

Attachment: Product Information: Pembrolizumab [Keytruda] [PDF, 560.49 KB]

Attachment: Product Information: Pembrolizumab [Keytruda] [DOCX, 431.54 KB]

Attachment: Extract from Clinical Evaluation Report: Pembrolizumab [Keytruda] [PDF, 1.88 MB]

Attachment: Extract from Clinical Evaluation Report: Pembrolizumab [Keytruda] [DOCX, 11.6 MB]

Device/Product Name

Keytruda

Active ingredients

Pembrolizumab

AusPAR Date

30 May 2018

Published

26 June 2018

Submission Number

PM-2016–02736-1-4

Submission Type

Extension of indications

Decision

Approved

Product types

Prescription medicines